UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
November 3, 2003
ANTIGENICS INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-29089 06-1562417
(State or other (Commission file number) (I.R.S. Employer Identification No.)
jurisdiction of
incorporation of
organization)
630 FIFTH AVENUE, SUITE 2100
NEW YORK, NEW YORK 10111
(Address of principal executive offices and zip code)
(212) 994-8200
(Registrant's telephone number, including area code)
Item 5. Other Events and Regulation FD Disclosure
On November 3, 2003, Antigenics Inc. announced that Renu Gupta, MD, has
joined the company as senior vice president of development, a new position that
will be responsible for regulatory affairs, clinical development, and program
and portfolio management. Antigenics also announced changes in senior
management. As of April 1, 2004, Elma Hawkins, PhD, currently the company's vice
chairman, will become senior advisor to the CEO. In addition, Antigenics' chief
medical officer Jonathan Lewis, MD, PhD, has left the company. The
responsibilities of Drs. Hawkins and Lewis will be absorbed within Antigenics'
newly restructured senior management team. The full text of the press release
issued in connection with the announcement is attached as Exhibit 99.1 to this
current report on Form 8-K.
Item 7. Financial Statements and Exhibits.
(c) Exhibits:
99.1 Press Release dated November 3, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANTIGENICS INC.
Date: November 3, 2003 By: /s/ Garo H. Armen
-----------------
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer
EXHIBIT INDEX
The following designated exhibits are filed herewith:
Exhibits:
99.1 Press Release dated November 3, 2003